Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.
Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.
Has no approved product and no sales; it funds its trials by selling new shares and could later be paid through sales of an approved drug or through licensing deals. It became a public company in 2023 by merging with Magenta Therapeutics, an already-listed biotech.
Moat: none (IP / patents). Clinical-stage biotech with patent-protected antibody candidates but no approved products or revenue yet.
Headquarters: New York City, US · Founded: 2022 · Employees: 92
Size Dianthus Therapeutics (DNTH) is a United States Health Care company (Biotechnology) with a market value of $4.73B, the 1216th largest of 3,085 United States companies the cockpit tracks. Shares closed at $83.98 on 18 Nov 2026.
Performance Over six months the shares fell 5.3%, against +2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 11.7% over the last twelve months (peer median +8.3%); the operating margin is -8,683.9% (peer median -15.6%).
Valuation It trades at 1,432.1× enterprise value to sales against a peer median of 12.7× (2nd most expensive of 16).
Capital Return on invested capital runs 58.5 points below its cost of capital (12.4% WACC).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.72M | $2.04M | $6.24M | $2.83M | $6.42M |
| Revenue growth | — | -67% | +121% | -56% | — |
| Gross profit | $2.33M | $1.61M | $5.82M | $2.47M | $6.27M |
| EBITDA | -$236M | -$178M | -$101M | -$47.8M | -$29.6M |
| Net income | -$202M | -$162M | -$85.0M | -$43.6M | -$28.5M |
| Free cash flow | -$176M | -$129M | -$78.3M | -$37.0M | -$29.2M |
| Capital expenditure | $697,000 | $213,000 | $105,000 | $110,000 | $139,000 |
| Total debt | $1.21M | $1.39M | $1.49M | $585,000 | $788,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics DNTH | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
| Immunovant IMVT | $6.86B | -7% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Annexon ANNX | $671M | -30% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DNTH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.6% | -7.7% | 5th highest of 21 |
| 6-month return | -5.3% | +2.0% | 8th lowest of 21 |
| Distance from 52-week high | -28.8% | -33.1% | 9th highest of 21 |
| Revenue growth (TTM) | -11.7% | +8.3% | 7th lowest of 16 |
| Operating margin | -8,683.9% | -15.6% | 2nd lowest of 16 |
| EV / Sales | 1,432.1× | 12.7× | 2nd most expensive of 16 |
| ROIC minus cost of capital | -58.5 pp | -9.8 pp | 2nd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 4.8× | 25.4% | +15.6% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |